Log in

Medifast Stock Forecast, Price & News

-0.33 (-0.19 %)
(As of 09/19/2020 12:07 AM ET)
Today's Range
Now: $173.61
50-Day Range
MA: $167.36
52-Week Range
Now: $173.61
Volume231,200 shs
Average Volume284,801 shs
Market Capitalization$2.04 billion
P/E Ratio27.13
Dividend Yield2.60%
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. The company sells its products through various channels, including the Internet, call centers, independent health advisors, franchise weight loss clinics, and direct consumer marketing. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
Read More
Medifast logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products



Sales & Book Value

Annual Sales$713.67 million
Cash Flow$6.50 per share
Book Value$9.03 per share


Net Income$77.92 million


Market Cap$2.04 billion
Next Earnings Date11/5/2020 (Estimated)
-0.33 (-0.19 %)
(As of 09/19/2020 12:07 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Medifast (NYSE:MED) Frequently Asked Questions

How has Medifast's stock price been impacted by COVID-19 (Coronavirus)?

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 146.5% and is now trading at $173.61.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Medifast?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medifast

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Medifast

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) announced its quarterly earnings data on Wednesday, August, 5th. The specialty retailer reported $1.96 EPS for the quarter, topping the consensus estimate of $1.84 by $0.12. The specialty retailer earned $220 million during the quarter, compared to the consensus estimate of $194.75 million. Medifast had a return on equity of 68.55% and a net margin of 10.04%.
View Medifast's earnings history

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, September 10th. Shareholders of record on Tuesday, September 22nd will be given a dividend of $1.13 per share on Friday, November 6th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.60%. The ex-dividend date is Monday, September 21st.
View Medifast's dividend history

What price target have analysts set for MED?

4 Wall Street analysts have issued twelve-month price targets for Medifast's stock. Their forecasts range from $90.00 to $220.00. On average, they expect Medifast's stock price to reach $163.33 in the next twelve months. This suggests that the stock has a possible downside of 5.9%.
View analysts' price targets for Medifast

Are investors shorting Medifast?

Medifast saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 962,400 shares, a drop of 25.4% from the August 15th total of 1,290,000 shares. Based on an average daily trading volume, of 279,300 shares, the short-interest ratio is currently 3.4 days. Approximately 8.6% of the shares of the company are sold short.
View Medifast's Short Interest

Who are some of Medifast's key competitors?

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), AbbVie (ABBV), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Adobe (ADBE), Cisco Systems (CSCO) and Exxon Mobil (XOM).

Who are Medifast's key executives?

Medifast's management team includes the following people:
  • Mr. Daniel R. Chard, CEO & Director (Age 54)
  • Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
  • Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
  • Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
  • Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.33%), Bank of New York Mellon Corp (1.99%), Principal Financial Group Inc. (1.68%), Principal Financial Group Inc. (1.69%), Charles Schwab Investment Management Inc. (0.99%) and Nordea Investment Management AB (0.87%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael A Hoer, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast

Which major investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including 13D Management LLC, Federated Hermes Inc., Vanguard Group Inc., Man Group plc, Bank of America Corp DE, Cubist Systematic Strategies LLC, WINTON GROUP Ltd, and Snow Capital Management LP. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast

Which major investors are buying Medifast stock?

MED stock was acquired by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Canada Pension Plan Investment Board, Jacobs Levy Equity Management Inc., Principal Financial Group Inc., Principal Financial Group Inc., Nuveen Asset Management LLC, Euclidean Technologies Management LLC, and Mackay Shields LLC. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Jeffrey J Brown, and Michael A Hoer.
View insider buying and selling activity for Medifast

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $173.61.

How big of a company is Medifast?

Medifast has a market capitalization of $2.04 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.